|
시장보고서
상품코드
1605916
표적 단백질 분해 시장 규모, 점유율, 동향, 산업 분석 보고서 : 유형별, 치료 분야별, 투여 경로별, 지역별 - 시장 예측(2025-2034년)Targeted Protein Degradation Market Size, Share, Trends, Industry Analysis Report: By Type, Therapeutic Area, Route of Administration, and Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 세계 표적 단백질 분해 시장 규모는 2034년까지 35억 4,791만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
표적 단백질 분해(TPD) 시장은 정밀의료의 발전과 생명공학에 대한 투자 증가에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 주요 원동력은 지금까지 '치료할 수 없었던' 단백질을 표적으로 삼는 TPD의 잠재력으로, 암 및 신경 퇴행성 질환과 같은 복잡한 질병에 대한 새로운 치료법을 제시할 수 있다는 점입니다.
제약사들이 학계 및 하이테크 기업들과 협력하여 새로운 분해제를 개발함에 따라 이 시장 개척 기회는 예측 기간 동안 증가할 것으로 예상됩니다. 맞춤형 의료에 대한 새로운 트렌드와 저분자 치료제에 대한 관심 증가도 시장 수요를 촉진하고 있습니다. 전반적으로 연구 활동과 임상시험이 증가함에 따라 TPD 시장은 빠르게 성장할 것으로 예상됩니다.
표적 단백질 분해 시장 보고서 하이라이트
유형별로는 단백질 분해 표적 키메라 분자(PROTACs) 분야가 시장을 주도하고 있으며, 광범위한 단백질을 분해할 수 있어 널리 사용되고 있습니다. 데글로니미드는 저분자 치료제의 발전에 힘입어 빠른 성장이 예상됩니다.
치료 분야별로 보면 암 치료가 표적 단백질 분해에 크게 의존하고 있어 암 질환 분야가 가장 큰 비중을 차지하고 있습니다. 신경질환 분야는 알츠하이머병 등 신경퇴행성 질환에 대한 연구가 증가함에 따라 급격한 성장이 예상됩니다.
투여 경로별로는 정맥 투여가 시장을 독점하고 있습니다. 정맥 투여는 특히 직접적이고 통제된 전달이 필요한 치료에 사용됩니다.
북미는 강력한 R&D 활동과 의약품에 대한 투자로 TPD 시장을 선도하고 있습니다. 아시아태평양은 의료비 지출 증가, 생명공학 분야의 성장, 혁신적인 치료법에 대한 관심 증가로 인해 가장 빠르게 성장하는 지역입니다.
이 시장의 주요 기업으로는 아르비나스(Arvinas), 카이메라 테라퓨틱스(Kymera Therapeutics), 누릭스 테라퓨틱스(Nurix Therapeutics) 등이 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 표적 단백질 분해 시장 인사이트
- 시장 현황
- 표적 단백질 분해 시장 역학
- 성장 촉진요인과 기회
- 종양학 애플리케이션 확대
- 신경질환 치료 증가
- 성장 억제요인과 과제
- 의약품 개발과 임상 검증의 복잡성
- 성장 촉진요인과 기회
- PESTEL 분석
- 표적 단백질 분해 시장 애플리케이션 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 표적 단백질 분해 시장 : 유형별
- 주요 조사 결과
- 소개
- 데그로니미드
- 면역조절제(IMiD)
- 단백질 분해 표적 키메라 분자(PROTAC)
- 돌발성 망막 변성 증후군(SARD)
- 선택적 에스트로겐 수용체 분해약(SERD)
- 기타
제6장 세계의 표적 단백질 분해 시장 : 치료 분야별
- 주요 조사 결과
- 소개
- 염증성 질환
- 신경질환
- 종양성 질환
- 호흡기질환
- 기타
제7장 세계의 표적 단백질 분해 시장 : 투여 경로별
- 주요 조사 결과
- 소개
- 경구
- 정맥내
- 기타
제8장 세계의 표적 단백질 분해 시장 : 지역별
- 주요 조사 결과
- 소개
- 표적 단백질 분해 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 유형별, 2020-2034년
- 북미 : 치료 분야별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 유형별, 2020-2034년
- 유럽 : 치료 분야별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 유형별, 2020-2034년
- 아시아태평양 : 치료 분야별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 유형별, 2020-2034년
- 중동 및 아프리카 : 치료 분야별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 유형별, 2020-2034년
- 라틴아메리카 : 치료 분야별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Arvinas
- Kymera Therapeutics
- Nurix Therapeutics
- C4 Therapeutics
- Foghorn Therapeutics
- Zymeworks
- Bristol-Myers Squibb
- Pfizer
- AbbVie
- Molteni Farmaceutici
The global targeted protein degradation market size is expected to reach USD 3547.91 million by 2034, according to a new study by Polaris Market Research. The report "Targeted Protein Degradation Market Size, Share, Trends, Industry Analysis Report: By Type, Therapeutic Area (Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, and Others), Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The targeted protein degradation (TPD) market is experiencing significant growth, driven by advances in precision medicine and increased investments in biotechnology. A key driver is the potential of TPD to target previously "undruggable" proteins, opening new therapeutic avenues for complex diseases such as cancer and neurodegenerative disorders.
Opportunities in this market are expected to rise during the forecast period as pharmaceutical companies collaborate with academic institutions and tech firms to develop novel degraders. The emerging trend toward personalized medicine and the growing focus on small-molecule therapeutics also fuel market demand. Overall, with increasing research activities and clinical trials, the TPD market is poised for rapid expansion.
Targeted Protein Degradation Market Report Highlights:
Based on type, the proteolysis-targeting chimeric molecules (PROTACs) segment dominates the market, being widely adopted due to their ability to degrade a broad range of proteins. Degronimids are expected to witness rapid growth, driven by advancements in small-molecule therapeutics.
In terms of therapeutic area, the oncological disorders segment holds the largest share, as cancer treatments heavily rely on targeted protein degradation. The neurological disorders segment is projected to grow rapidly, with increasing research on neurodegenerative diseases such as Alzheimer's.
By route of administration, the intravenous segment dominates the market; the IV route is especially used for therapies requiring direct and controlled delivery.
North America leads the TPD market, owing to strong R&D activities and pharmaceutical investments. Asia Pacific is the fastest-growing region, driven by rising healthcare expenditure, growing biotechnology sectors, and an increasing focus on innovative therapies.
Some of the key players in the market are Arvinas, Kymera Therapeutics, and Nurix Therapeutics.
Polaris Market Research has segmented the targeted protein degradation market report on the basis of type, therapeutic area, route of administration, and region:
By Type Outlook (Revenue - USD Million, 2020-2034)
- Degronimids
- Immunomodulatory Drugs (IMiDs)
- Proteolysis-Targeting Chimeric Molecules (PROTACs)
- Sudden Acquired Retinal Degeneration Syndrome (SARDs)
- Selective Estrogen Receptor Degraders (SERDs)
- Others
By Therapeutic Area Outlook (Revenue - USD Million, 2020-2034)
- Inflammatory Disorders
- Neurological Disorders
- Oncological Disorders
- Respiratory Disorders
- Others
By Route of Administration Outlook (Revenue - USD Million, 2020-2034)
- Oral
- Intravenous
- Others
By Regional Outlook (Revenue - USD Million, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Targeted Protein Degradation Market Insights
- 4.1. Targeted Protein Degradation Market - Market Snapshot
- 4.2. Targeted Protein Degradation Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Expansion in Oncology Applications
- 4.2.1.2. Rise in Neurological Disorder Treatments
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Complexity of Drug Development and Clinical Validation
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Targeted Protein Degradation Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Targeted Protein Degradation Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 5.3. Degronimids
- 5.3.1. Global Targeted Protein Degradation Market, by Degronimids, by Region, 2020-2034 (USD Million)
- 5.4. Immunomodulatory Drugs (IMiDs)
- 5.4.1. Global Targeted Protein Degradation Market, by Immunomodulatory Drugs (IMiDs), by Region, 2020-2034 (USD Million)
- 5.5. Proteolysis-Targeting Chimeric Molecules (PROTACs)
- 5.5.1. Global Targeted Protein Degradation Market, by Proteolysis-Targeting Chimeric Molecules (PROTACs), by Region, 2020-2034 (USD Million)
- 5.6. Sudden Acquired Retinal Degeneration Syndrome (SARDs)
- 5.6.1. Global Targeted Protein Degradation Market, by Sudden Acquired Retinal Degeneration Syndrome (SARDs), by Region, 2020-2034 (USD Million)
- 5.7. Selective Estrogen Receptor Degraders (SERDs)
- 5.7.1. Global Targeted Protein Degradation Market, by Selective Estrogen Receptor Degraders (SERDs), by Region, 2020-2034 (USD Million)
- 5.8. Others
- 5.8.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)
6. Global Targeted Protein Degradation Market, by Therapeutic Area
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 6.3. Inflammatory Disorders
- 6.3.1. Global Targeted Protein Degradation Market, by Inflammatory Disorders, by Region, 2020-2034 (USD Million)
- 6.4. Neurological Disorders
- 6.4.1. Global Targeted Protein Degradation Market, by Neurological Disorders, by Region, 2020-2034 (USD Million)
- 6.5. Oncological Disorders
- 6.5.1. Global Targeted Protein Degradation Market, by Oncological Disorders, by Region, 2020-2034 (USD Million)
- 6.6. Respiratory Disorders
- 6.6.1. Global Targeted Protein Degradation Market, by Respiratory Disorders, by Region, 2020-2034 (USD Million)
- 6.7. Others
- 6.7.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)
7. Global Targeted Protein Degradation Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 7.3. Oral
- 7.3.1. Global Targeted Protein Degradation Market, by Oral, by Region, 2020-2034 (USD Million)
- 7.4. Intravenous
- 7.4.1. Global Targeted Protein Degradation Market, by Intravenous, by Region, 2020-2034 (USD Million)
- 7.5. Others
- 7.5.1. Global Targeted Protein Degradation Market, by Others, by Region, 2020-2034 (USD Million)
8. Global Targeted Protein Degradation Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Targeted Protein Degradation Market Assessment, By Geography, 2020-2034 (USD Million)
- 8.3. Targeted Protein Degradation Market - North America
- 8.3.1. North America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.3.2. North America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.3.3. North America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.4. Targeted Protein Degradation Market - US
- 8.3.4.1. US: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.3.4.2. US: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.3.4.3. US: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.5. Targeted Protein Degradation Market - Canada
- 8.3.5.1. Canada: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.3.5.2. Canada: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.3.5.3. Canada: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4. Targeted Protein Degradation Market - Europe
- 8.4.1. Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.2. Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.3. Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.4. Targeted Protein Degradation Market - UK
- 8.4.4.1. UK: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.4.2. UK: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.4.3. UK: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.5. Targeted Protein Degradation Market - France
- 8.4.5.1. France: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.5.2. France: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.5.3. France: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.6. Targeted Protein Degradation Market - Germany
- 8.4.6.1. Germany: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.6.2. Germany: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.6.3. Germany: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.7. Targeted Protein Degradation Market - Italy
- 8.4.7.1. Italy: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.7.2. Italy: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.7.3. Italy: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.8. Targeted Protein Degradation Market - Spain
- 8.4.8.1. Spain: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.8.2. Spain: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.8.3. Spain: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.9. Targeted Protein Degradation Market - Netherlands
- 8.4.9.1. Netherlands: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.9.2. Netherlands: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.9.3. Netherlands: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.10. Targeted Protein Degradation Market - Russia
- 8.4.10.1. Russia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.10.2. Russia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.10.3. Russia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.11. Targeted Protein Degradation Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.4.11.2. Rest of Europe: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.4.11.3. Rest of Europe: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5. Targeted Protein Degradation Market - Asia Pacific
- 8.5.1. Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.2. Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.3. Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.4. Targeted Protein Degradation Market - China
- 8.5.4.1. China: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.4.2. China: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.4.3. China: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.5. Targeted Protein Degradation Market - India
- 8.5.5.1. India: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.5.2. India: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.5.3. India: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.6. Targeted Protein Degradation Market - Malaysia
- 8.5.6.1. Malaysia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.6.2. Malaysia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.6.3. Malaysia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.7. Targeted Protein Degradation Market - Japan
- 8.5.7.1. Japan: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.7.2. Japan: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.7.3. Japan: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.8. Targeted Protein Degradation Market - Indonesia
- 8.5.8.1. Indonesia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.8.2. Indonesia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.8.3. Indonesia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.9. Targeted Protein Degradation Market - South Korea
- 8.5.9.1. South Korea: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.9.2. South Korea: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.9.3. South Korea: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.10. Targeted Protein Degradation Market - Australia
- 8.5.10.1. Australia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.10.2. Australia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.10.3. Australia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.11. Targeted Protein Degradation Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.5.11.2. Rest of Asia Pacific: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.5.11.3. Rest of Asia Pacific: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6. Targeted Protein Degradation Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.2. Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.3. Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.4. Targeted Protein Degradation Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.4.2. Saudi Arabia: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.4.3. Saudi Arabia: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.5. Targeted Protein Degradation Market - UAE
- 8.6.5.1. UAE: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.5.2. UAE: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.5.3. UAE: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.6. Targeted Protein Degradation Market - Israel
- 8.6.6.1. Israel: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.6.2. Israel: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.6.3. Israel: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.7. Targeted Protein Degradation Market - South Africa
- 8.6.7.1. South Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.7.2. South Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.7.3. South Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.8. Targeted Protein Degradation Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.6.8.2. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.6.8.3. Rest of Middle East & Africa: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7. Targeted Protein Degradation Market - Latin America
- 8.7.1. Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.7.2. Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.7.3. Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.4. Targeted Protein Degradation Market - Mexico
- 8.7.4.1. Mexico: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.7.4.2. Mexico: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.7.4.3. Mexico: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.5. Targeted Protein Degradation Market - Brazil
- 8.7.5.1. Brazil: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.7.5.2. Brazil: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.7.5.3. Brazil: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.6. Targeted Protein Degradation Market - Argentina
- 8.7.6.1. Argentina: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.7.6.2. Argentina: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.7.6.3. Argentina: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.7. Targeted Protein Degradation Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Targeted Protein Degradation Market, by Type, 2020-2034 (USD Million)
- 8.7.7.2. Rest of Latin America: Targeted Protein Degradation Market, by Therapeutic Area, 2020-2034 (USD Million)
- 8.7.7.3. Rest of Latin America: Targeted Protein Degradation Market, by Route of Administration, 2020-2034 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Arvinas
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Kymera Therapeutics
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Nurix Therapeutics
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. C4 Therapeutics
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Foghorn Therapeutics
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Zymeworks
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Bristol-Myers Squibb
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Pfizer
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. AbbVie
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Molteni Farmaceutici
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
샘플 요청 목록